logo-loader

Tiziana Life Sciences' lead candidate demonstrates favorable safety profile and clinical response

Last updated: 13:23 05 Mar 2024 GMT, First published: 19:00 22 Dec 2020 GMT

Snapshot

  • Tiziana Life Sciences to present positive data for lead drug candidate in Alzheimer’s disease
  • Tiziana Life Sciences: Analyst shares his feedback from key opinion leader call on Foralumab
  • Tiziana Life Sciences reveals "exciting" clinical data from latest MS trial
Tiziana Life Sciences - Tiziana Life Sciences upbeat on potential for coronavirus treatment

About the company

Tiziana Life Sciences Ltd is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy.

The company’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery.

Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date.

How it is doing

05 Mar 2024

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the chairman of its scientific advisory board, Dr Howard Weiner, will present positive data on intranasal anti-CD3 monoclonal antibody (mAb) in models of Alzheimer’s and Parkinson’s disease at an upcoming conference.

He will deliver the update at AD/PD, the annual international conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, which is being held in Lisbon, Portugal from March 5 to 9.

The data is from the company’s research and development of its lead drug candidate intranasal foralumab, an anti-CD3 mAb.

“Our research has demonstrated that intranasal rodent anti-CD3 mAb and intranasal fully human anti-CD3 mAb (foralumab) will decrease microglia activation in rodents and humans, respectively,” Dr Weiner said in a statement.

08 Jan 2024

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients, which have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale (MFIS). 

The clinical-stage biopharmaceutical company said PET scan findings showing a reduction in microglial activation were also seen in the six patients with MFIS score improvement at the three-month evaluation period.   

05 Jan 2024

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has filed a new patent application relating to the composition and methods for combining a GLP-1 receptor agonist (ra) and foralumab, its lead drug candidate, to further reduce system and vascular inflammation associated with Type 2 diabetes (T2D) and also in patients with non-T2D obesity.

The company said that the patent application describes the potential for foralumab, which is a fully human anti-CD3 antibody, to provide additional risk reduction for heart attack, stroke, and peripheral vascular disease when combined with a GLP-1ra in this patient population.

What the brokers say

15 Mar 2022

Zak’s Small Cap Research has provided its feedback from a ‘key opinion leader virtual event’ hosted by Tiziana Life Sciences Ltd.

The set-piece was organized after the publication of encouraging data from a trial of Tiziana’s lead drug, which was used to treat a single patient with secondary progressive multiple sclerosis, an advanced form of the disease.

Signs of efficacy were detected, while Tiziana’s nasally administered Foralumab was well tolerated and there were no adverse effects in the six months of therapy, which will be continued.

What management says

16 Oct 2023

Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company announced some fresh clinical results from its work in treating non-active secondary progressive multiple sclerosis (MS) with intranasal foralumab.

The work has focused particularly on reducing the amount of fatigue experienced by MS sufferers. Davis emphasises that the fatigue experienced by MS patients is not the typical tiredness most people feel, but a debilitating condition that severely impacts their quality of life.

In Tiziana's expanded access programme, four out of six patients showed a reduction in this fatigue - a ratio Davis describes as "exciting" considering the severe impact of fatigue on MS sufferers.

Proactive Research

28 Jul 2023

Tiziana is close to being able to start the important phase IIa study with its lead product, intranasal foralumab, in non-active secondary progressive multiple sclerosis (SPMS) and is well advanced in its plan to initiate a separate study in Alzheimer's disease (AD).

Proactive Analyst expects "some good news over the next 1-2 months" from...

Proactive Research Analyst Robin Davison talks to Thomas Warner about his new research note on Tiziana Life Sciences Ltd (NASDAQ:TLSA), which focuses on what he expects from the clinical-stage biopharmaceutical company over the next few months. He says Tiziana is approaching a significant...

on 28/7/23